| Today’s Big NewsFeb 27, 2025 |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today! 
|
|
| By Fraiser Kansteiner As part of a new strategic restructuring to streamline its American operations, Eisai plans to lay off approximately 121 employees across various U.S. functions, a company spokesperson told Fierce Pharma on Thursday. The restructuring will primarily affect commercial, medical and corporate service functions. |
|
|
|
By Nick Paul Taylor Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is taking the program forward independently having regained full rights to the asset. |
By James Waldron Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in hepatitis B while it seeks a suitable partner. |
By Darren Incorvaia Even as President Donald Trump wages a very public fight against diversity, equity and inclusion initiatives in the government and beyond, several large drugmakers say running diverse clinical trials is not optional or extraneous, but a core part of the work they do. |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT Softgels have emerged as a versatile dosage form, yet they are often overlooked. This webinar will explore the role of softgels in both early-stage and post-approval lifecycle management strategies. Learn about key considerations for launching with softgels, opportunities for post-approval switches to or from softgels, and how softgels compare to other dose forms. Register now. 
|
|
By Kevin Dunleavy With sales of $103 million in the fourth quarter and $180 million in its first nine months on the market, Madrigal Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis (MASH) treatment Rezdiffra has all the earmarks of a soon-to-be blockbuster. |
By Eric Sagonowsky Disruptions to government-sanctioned advisory committee meetings on vaccines are becoming increasingly common after the recent confirmation of Robert F. Kennedy Jr. as secretary of the Department of Health and Human Services. |
By Darren Incorvaia The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that the prior administration struck with Moderna, according to a report in Bloomberg. The move comes as bird flu continues to spread throughout chickens and dairy cows, occasionally jumping into humans as well. |
By Angus Liu On BeiGene’s very first live earnings call, CEO and co-founder John Oyler described a “once-in-a-lifetime opportunity.” To him, the company’s potential in chronic lymphocytic leukemia is akin to two other legendary Big Biotech stories—Gilead in HIV and Vertex in cystic fibrosis. |
By Conor Hale Teleflex announced plans to split into two companies—and is setting up one scion with cath lab assets from Biotronik. |
By Nick Paul Taylor Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral prospects to weight loss of 2.9% after 13 weeks of treatment. |
By Fraiser Kansteiner After receiving a rare pediatric disease priority review voucher in tandem with Miplyffa’s FDA green light in September, Zevra has locked in a deal to sell the voucher for $150 million. The cash from the sale will be used to fuel R&D, plus the commercial rollouts of Miplyffa and the urea cycle disorder medicine Olpruva, which Zevra picked up in its $91 million buyout of Acer Therapeutics, the company said. |
Fierce podcasts Don’t miss an episode |
| Senior Editor Heather Landi, Senior Writer Paige Minemyer and Staff Writer Emma Beavins reflect on their trip to the ViVE conference in Nashville and what they learned. |
|
|---|
|
|
|
Tuesday, March 4, 2025 | 2pm ET / 11am PT Learn expert strategies for overcoming the unique challenges of early phase clinical trials, from preparing investigational products to maintaining blinding and sourcing controlled substances. This webinar provides actionable insights to optimize pharmacy activities and ensure trial success. Register now. 
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| Submissions Open Early August |
|
|
| |
|
